The PA207 peptide inhibitor of LIM-only protein 2 (Lmo2) targets zinc finger domains in a non-specific manner

Protein and Peptide Letters

Volumn 21, Issue 2, 2014, Pages 132-139

  Wilkinson White, Lorna ^a   Matthews, Jacqueline M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemical shift perturbation experiments; Lmo2; Peptide aptamer; Peptide protein interaction; Protein destabilisation; Zinc co ordination

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; GLUTATHIONE TRANSFERASE; LIM DOMAIN BINDING PROTEIN 1; LIM ONLY PROTEIN 2; PA 207; PEPTIDE APTAMER; REGULATOR PROTEIN; THIOREDOXIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG PROTEIN BINDING; IN VITRO STUDY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN UNFOLDING;

DNA-BINDING PROTEINS; PEPTIDES; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEIN UNFOLDING; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS; ZINC; ZINC FINGERS;

EID: 84893293805     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660116     Document Type: Article

References (31)

1. (a) Royer-Pokora, B.; Loos, U.; Ludwig, W.D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene, 1991, 6, 1887-93
2. (b) Van Vlierberghe, P.; van Grotel, M.; Beverloo, H.B.; Lee, C.; Helgason, T.; Buijs-Gladdines, J.; Passier, M.; van Wering, E.R.; Veerman, A.J.; Kamps, W.A.; Meijerink, J.P.; Pieters, R. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood, 2006, 108, 3520-9.
3. (a) Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G.P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K.; Asnafi, V.; MacIntyre, E.; Dal Cortivo, L.; Radford, I.; Brousse, N.; Sigaux, F.; Moshous, D.; Hauer, J.; Borkhardt, A.; Belohradsky, B.H.; Wintergerst, U.; Velez, M.C.; Leiva, L.; Sorensen, R.; Wulffraat, N.; Blanche, S.; Bushman, F.D.; Fischer, A.; Cavazzana-Calvo, M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 2008, 118, 3132-42
4. (b) Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D.; Gilmour, K.C.; Adams, S.; Thornhill, S.I.; Parsley, K.L.; Staal, F.J.; Gale, R.E.; Linch, D.C.; Bayford, J.; Brown, L.; Quaye, M.; Kinnon, C.; Ancliff, P.; Webb, D.K.; Schmidt, M.; von Kalle, C.; Gaspar, H.B.; Thrasher, A.J. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 2008, 118, 3143-50.
5. Visvader, J.E.; Mao, X.H.; Fujiwara, Y.; Hahm, K.; Orkin, S.H. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation. Proc. Natl. Acad. Sci. USA, 1997, 94, 13707-13712.
6. McCormack, M.P.; Young, L.F.; Vasudevan, S.; de Graaf, C.A.; Codrington, R.; Rabbitts, T.H.; Jane, S.M.; Curtis, D.J. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science, 2010, 327, 879-83.
7. Ma, S.; Guan, X.Y.; Beh, P.S.; Wong, K.Y.; Chan, Y.P.; Yuen, H.F.; Vielkind, J.; Chan, K.W. The significance of LMO2 expression in the progression of prostate cancer. J. Pathol., 2007, 211, 278-85.
8. Yamada, Y.; Pannell, R.; Forster, A.; Rabbitts, T.H. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. Oncogene, 2002, 21, 1309-15.
9. Matthews, J.M.; Lester, K.; Joseph, S.; Curtis, D.J. LIM-domain-only proteins in cancer. Nat. Rev. Cancer, 2013, 13, 111-22.
10. Matthews, J.M.; Bhati, M.; Lehtomaki, E.; Mansfield, R.E.; Cubeddu, L.; Mackay, J.P. It takes two to tango: the structure and function of LIM, RING, PHD and MYND domains. Curr. Pharm. Des., 2009, 15, 3681-96.
11. (a) Tripic, T.; Deng, W.; Cheng, Y.; Zhang, Y.; Vakoc, C.R.; Gregory, G.D.; Hardison, R.C.; Blobel, G.A. SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood, 2009, 113, 2191-201
12. (b) Li, L.; Jothi, R.; Cui, K.; Lee, J.Y.; Cohen, T.; Gorivodsky, M.; Tzchori, I.; Zhao, Y.; Hayes, S.M.; Bresnick, E.H.; Zhao, K.; Westphal, H.; Love, P.E. Nuclear adaptor Ldb1 regulates a transcriptional program essential for the maintenance of hematopoietic stem cells. Nat. Immunol., 2011, 12, 129-36
13. (c) Manaia, A.; Lemarchandel, V.; Klaine, M.; Max-Audit, I.; Romeo, P.; Dieterlen-Lievre, F.; Godin, I. Lmo2 and GATA-3 associated expression in intraembryonic hemogenic sites. Development, 2000, 127, 643-53.
14. Nam, C.H.; Lobato, M.N.; Appert, A.; Drynan, L.F.; Tanaka, T.; Rabbitts, T.H. An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions. Oncogene, 2008, 27, 4962-8.
15. Appert, A.; Nam, C.H.; Lobato, N.; Priego, E.; Miguel, R.N.; Blundell, T.; Drynan, L.; Sewell, H.; Tanaka, T.; Rabbitts, T. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. Cancer Res., 2009, 69, 4784-90.
16. (a) Deane, J.E.; Maher, M.J.; Langley, D.B.; Graham, S.C.; Visvader, J.E.; Guss, J.M.; Matthews, J.M. Crystallization of FLINC4, an intramolecular LMO4-ldb1 complex. Acta Crystallogr. D Biol. Crystallogr., 2003, 59, 1484-6
17. (b) Deane, J.E.; Ryan, D.P.; Sunde, M.; Maher, M.J.; Guss, J.M.; Visvader, J.E.; Matthews, J.M. Tandem LIM domains provide synergistic binding in the LMO4:Ldb1 complex. EMBO J., 2004, 23, 3589-98.
18. (a) El Omari, K.; Hoosdally, S.J.; Tuladhar, K.; Karia, D.; Vyas, P.; Patient, R.; Porcher, C.; Mancini, E.J. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood, 2010, 117, 2146-2156
19. (b) Dastmalchi, S.; Wilkinson-White, L.; Kwan, A.H.; Gamsjaeger, R.; Mackay, J.P.; Matthews, J.M. Solution structure of a tethered Lmo2(LIM2) /Ldb1(LID) complex. Protein Sci., 2012, 21, 1768-74.
20. Wilkinson-White, L.E.; Dastmalchi, S.; Kwan, A.H.; Ryan, D.P.; Mackay, J.P.; Matthews, J.M. (1)H, (15)N and (13)C assignments of an intramolecular Lmo2-LIM2/Ldb1-LID complex. Biomol. NMR Assign., 2010, 4, 203-206.
21. Ryan, D.P.; Sunde, M.; Kwan, A.H.Y.; Marianayagam, N.J.; Nancarrow, A.L.; Hoven, R.N.V.; Thompson, L.S.; Baca, M.; Mackay, J.P.; Visvader, J.E.; Matthews, J.M. Identification of the key LMO2-binding determinants on Ldb1. J. Mol. Biol., 2006, 359, 66-75.
22. Murphy, J.B.; Kies, M.W. Note on spectrophotometric determination of proteins in dilute solutions. Biochim. Biophys. Acta, 1960, 45, 382-384.
23. Deane, J.E.; Sum, E.; Mackay, J.P.; Lindeman, G.J.; Visvader, J.E.; Matthews, J.M. Design, production and characterization of FLIN2 and FLIN4: the engineering of intramolecular ldb1: LMO complexes. Prot. Eng., 2001, 14, 493-499.
24. Deane, J.E.; Mackay, J.P.; Kwan, A.H.Y.; Sum, E.Y.M.; Visvader, J.E.; Matthews, J.M. Structural basis for the recognition of ldb1 by the N-terminal LIM domains of LMO2 and LMO4. EMBO J., 2003, 22, 2224-2233.
25. (a) Jeffries, C.M.; Graham, S.C.; Stokes, P.H.; Collyer, C.A.; Guss, J.M.; Matthews, J.M. Stabilization of a binary protein complex by intein-mediated cyclization. Protein Sci., 2006, 15, 2612-8
26. (b) Bhati, M.; Lee, C.; Gadd, M.S.; Jeffries, C.M.; Kwan, A.; Whitten, A.E.; Trewhella, J.; Mackay, J.P.; Matthews, J.M. Solution structure of the LIM-homeodomain transcription factor complex Lhx3/Ldb1 and the effects of a pituitary mutation on key Lhx3 interactions. PLoS ONE, 2012, 7, e40719.
27. Kwan, A.H.; Mobli, M.; Gooley, P.R.; King, G.F.; Mackay, J.P. Macromolecular NMR spectroscopy for the non-spectroscopist. FEBS J., 2011, 278, 687-703.
28. Maret, W. New perspectives of zinc coordination environments in proteins. J. Inorg. Biochem., 2012, 111, 110-6.
29. Bresnick, E.H.; Katsumura, K.R.; Lee, H.Y.; Johnson, K.D.; Perkins, A.S. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucl. Acids Res., 2012, 40, 5819-5831.
30. Bhati, M.; Lee, C.; Nancarrow, A.L.; Lee, M.; Craig, V.J.; Bach, I.; Guss, J.M.; Mackay, J.P.; Matthews, J.M. Implementing the LIM code: the structural basis for cell type-specific assembly of LIM-homeodomain complexes. EMBO J., 2008, 27, 2018-29.
31. Jurata, L.W.; Kenny, D.A.; Gill, G.N. Nuclear LIM interactor, a rhombotin and LIM homeodomain interacting protein, is expressed early in neuronal development. Proc. Natl. Acad. Sci. USA, 1996, 93, 11693-8.